A
Anna Lena Törnqvist
Researcher at Lund University
Publications - 8
Citations - 919
Anna Lena Törnqvist is an academic researcher from Lund University. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 7, co-authored 8 publications receiving 847 citations.
Papers
More filters
Journal ArticleDOI
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease.
Elena Moro,Andres M. Lozano,Pierre Pollak,Yves Agid,Stig Rehncrona,Jens Volkmann,Jaime Kulisevsky,Jose A. Obeso,Alberto Albanese,Marwan Hariz,Marwan Hariz,Niall Quinn,Jans D. Speelman,A.L. Benabid,Valérie Fraix,Alexandre Mendes,Marie-Laure Welter,Jean-Luc Houeto,Philippe Cornu,Didier Dormont,Anna Lena Törnqvist,Ron Ekberg,Alfons Schnitzler,Lars Timmermann,Lars Wojtecki,Andres Gironell,Maria C. Rodriguez-Oroz,Jorge Guridi,Anna Rita Bentivoglio,Maria Fiorella Contarino,Luigi Romito,Massimo Scerrati,Massimo Scerrati,Marc Janssens,Anthony E. Lang +34 more
TL;DR: The 5 to 6 year follow‐up of a multicenter study of bilateral subthalamic nucleus and globus pallidus internus deep brain stimulation in advanced Parkinson's disease patients confirms the long‐term efficacy of STN and GPi DBS in advanced PD.
Journal ArticleDOI
Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments.
TL;DR: It is concluded that high‐frequency electric thalamic stimulation can efficiently suppress severe tremor in PD and ET more than 6 years after permanent implantation of brain electrodes.
Journal ArticleDOI
Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation.
TL;DR: The settings of amplitude and frequency have a major influence on the intelligibility of speech, emphasizing the importance of meticulous parameter adjustments when programming DBS to minimize side effects related to speech.
Journal ArticleDOI
Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data.
TL;DR: Important limitations of the SF-36 are demonstrated and the first evidence-based guidelines for its use in Parkinson's disease are provided, which are a general one for the clinical research community regarding requirements for reporting rating scale endpoints.
Journal ArticleDOI
First neuropathological description of a patient with Parkinson’s disease and LRRK2 p.N1437H mutation
Andreas Puschmann,Andreas Puschmann,Elisabet Englund,Owen A. Ross,Carles Vilariño-Güell,Carles Vilariño-Güell,Sarah Lincoln,Jennifer M. Kachergus,Stephanie A. Cobb,Anna Lena Törnqvist,Stig Rehncrona,Håkan Widner,Zbigniew K. Wszolek,Matthew J. Farrer,Matthew J. Farrer,Christer Nilsson +15 more
TL;DR: By screening DNA from seven brains of PD patients, one individual with seemingly sporadic PD and LRRK2 p.N1437H mutation is found, and Neuropathological examination revealed marked cell loss and moderate alpha-synuclein positive Lewy body pathology in the brainstem, temporolimbic regions and neocortex, and a striking finding was very pronounced ubiquitin-positive pathology.